Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells 1,250 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $39.18, for a total transaction of $48,975.00. Following the completion of the sale, the director now directly owns 263,774 shares of the company’s stock, valued at $10,334,665.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alec Machiels also recently made the following trade(s):

  • On Thursday, April 14th, Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $50.90, for a total transaction of $63,625.00.
  • On Tuesday, March 15th, Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $39.57, for a total transaction of $49,462.50.

Shares of APLS opened at $42.16 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.85 and a quick ratio of 8.58. The company’s 50 day simple moving average is $48.04 and its 200 day simple moving average is $44.60. Apellis Pharmaceuticals, Inc. has a 1 year low of $27.50 and a 1 year high of $73.00.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.07). Apellis Pharmaceuticals had a negative return on equity of 607.37% and a negative net margin of 866.81%. During the same quarter in the previous year, the company posted ($2.32) EPS. Sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -5.58 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Harbor Investment Advisory LLC raised its stake in Apellis Pharmaceuticals by 25.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,267 shares of the company’s stock worth $60,000 after purchasing an additional 254 shares during the period. Metropolitan Life Insurance Co NY raised its stake in Apellis Pharmaceuticals by 1.7% during the third quarter. Metropolitan Life Insurance Co NY now owns 17,657 shares of the company’s stock worth $582,000 after purchasing an additional 291 shares during the period. MML Investors Services LLC raised its stake in Apellis Pharmaceuticals by 4.6% during the third quarter. MML Investors Services LLC now owns 7,970 shares of the company’s stock worth $263,000 after purchasing an additional 354 shares during the period. Virginia Retirement Systems ET AL raised its stake in shares of Apellis Pharmaceuticals by 7.1% in the 1st quarter. Virginia Retirement Systems ET AL now owns 6,000 shares of the company’s stock valued at $305,000 after acquiring an additional 400 shares during the period. Finally, Swiss National Bank raised its stake in shares of Apellis Pharmaceuticals by 0.4% in the 3rd quarter. Swiss National Bank now owns 133,400 shares of the company’s stock valued at $4,397,000 after acquiring an additional 500 shares during the period. 76.50% of the stock is currently owned by institutional investors.

A number of equities research analysts have recently commented on APLS shares. Robert W. Baird upped their target price on shares of Apellis Pharmaceuticals from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, March 16th. Citigroup reissued a “focus list” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a report on Thursday, March 17th. The Goldman Sachs Group cut their price target on shares of Apellis Pharmaceuticals from $102.00 to $86.00 and set a “buy” rating for the company in a report on Monday, March 7th. Raymond James cut their price target on shares of Apellis Pharmaceuticals from $114.00 to $102.00 in a report on Thursday, May 5th. Finally, Roth Capital cut shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 price target for the company. in a report on Wednesday, April 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $69.87.

About Apellis Pharmaceuticals (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Recommended Stories

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.